Dickkopf-1 as a potential therapeutic target in Paget's disease of bone
McCarthy, Helen S. Marshall, Michael J.
McCarthy, Helen S.
Marshall, Michael J.
Citations
Altmetric:
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2010-01-08
Submitted Date
Collections
Other Titles
Abstract
This article discusses Dickkopf-1 (DKK-1), which is a soluble inhibitor of Wnt signalling and its excessive expression contributes to bone loss in rheumatoid arthritis and multiple myeloma. New therapeutics have been developed for treatment of these conditions that target DKK-1 expression. DKK-1 is elevated in serum of patients with Paget's disease of the bone (PDB) and evidence is accumulating for a role of DKK-1 in PDB. At present there is no cure for PDB and the current treatment of choice are bisphosphonates. These treat the resorptive phase of PDB but do not prevent its return. This article offers a new perspective on the aetiology of PDB and speculate on DKK-1 as a therapeutic target.
Citation
Expert Opinion on Therapeutic Targets, 2010, 14(2), pp. 221-230
Publisher
Ashley
Journal
Expert Opinion on Therapeutic Targets
Research Unit
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
This article is not available through ChesterRep.
Series/Report no.
ISSN
1472-8222
1744-7631
1744-7631